Antiretroviral therapy response among HIV-2 infected patients: a systematic review
- PMID: 25154616
- PMCID: PMC4156654
- DOI: 10.1186/1471-2334-14-461
Antiretroviral therapy response among HIV-2 infected patients: a systematic review
Abstract
Background: Few data are available on antiretroviral therapy (ART) response among HIV-2 infected patients. We conducted a systematic review on treatment outcomes among HIV-2 infected patients on ART, focusing on the immunological and virological responses in adults.
Methods: Data were extracted from articles that were selected after screening of PubMed/MEDLINE up to November 2012 and abstracts of the 1996-2012 international conferences. Observational cohorts, clinical trials and program reports were eligible as long as they reported data on ART response (clinical, immunological or virological) among HIV-2 infected patients. The determinants investigated included patients' demographic characteristics, CD4 cell count at baseline and ART received.
Results: Seventeen reports (involving 976 HIV-2 only and 454 HIV1&2 dually reactive patients) were included in the final review, and the analysis presented in this report are related to HIV-2 infected patients only. There was no randomized controlled trial and only two cohorts had enrolled more than 100 HIV-2 only infected patients. The median CD4 count at ART initiation was 165 cells/mm3, [IQR; 137-201] and the median age at ART initiation was 44 years (IQR: 42-48 years). Ten studies included 103 patients treated with three nucleoside reverse transcriptase inhibitors (NRTI). Protease inhibitor (PI) based regimens were reported by 16 studies. Before 2009, the most frequent PIs used were Nelfinavir and Indinavir, whereas it was Lopinavir/ritonavir thereafter. The immunological response at month-12 was reported in six studies and the mean CD4 cell count increase was +118 cells/μL (min-max: 45-200 cells/μL).
Conclusion: Overall, clinical and immuno-virologic outcomes in HIV-2 infected individuals treated with ART are suboptimal. There is a need of randomized controlled trials to improve the management and outcomes of people living with HIV-2 infection.
Figures
Similar articles
-
Lopinavir/ritonavir: a review of its use in the management of HIV infection.Drugs. 2003;63(8):769-802. doi: 10.2165/00003495-200363080-00004. Drugs. 2003. PMID: 12662125 Review.
-
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Cochrane Database Syst Rev. 2014. PMID: 24852077 Review.
-
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Cochrane Database Syst Rev. 2013. PMID: 23740608 Review.
-
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.BMC Pediatr. 2012 Jul 8;12:95. doi: 10.1186/1471-2431-12-95. BMC Pediatr. 2012. PMID: 22770231 Free PMC article. Clinical Trial.
-
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a. Pediatr Infect Dis J. 2008. PMID: 18382386
Cited by
-
Human Immunodeficiency Virus Type 2: The Neglected Threat.Pathogens. 2021 Oct 25;10(11):1377. doi: 10.3390/pathogens10111377. Pathogens. 2021. PMID: 34832533 Free PMC article. Review.
-
Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.Clin Infect Dis. 2021 Feb 1;72(3):369-378. doi: 10.1093/cid/ciaa277. Clin Infect Dis. 2021. PMID: 33527119 Free PMC article.
-
The first case of HIV-2 in Scotland.Access Microbiol. 2019 Dec 10;2(3):acmi000087. doi: 10.1099/acmi.0.000087. eCollection 2020. Access Microbiol. 2019. PMID: 32974567 Free PMC article.
-
Long-term immunological responses to treatment among HIV-2 patients in Côte d'Ivoire.BMC Infect Dis. 2020 Mar 12;20(1):213. doi: 10.1186/s12879-020-4927-x. BMC Infect Dis. 2020. PMID: 32164565 Free PMC article.
-
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.Clin Infect Dis. 2019 Jan 7;68(2):177-187. doi: 10.1093/cid/ciy463. Clin Infect Dis. 2019. PMID: 30052811 Free PMC article.
References
-
- da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, Anderssond S, Aaby P. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS. 2008;22(10):1195–1202. doi: 10.1097/QAD.0b013e328300a33d. - DOI - PubMed
-
- Mansson F, Camara C, Biai A, Monteiro M, da Silva ZJ, Dias F, Alves A, Andersson S, Fenyö EM, Norrgren H, Unemo M. High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa. Int J STD AIDS. 2010;21(9):631–635. doi: 10.1258/ijsa.2010.009584. - DOI - PubMed
-
- Rouet F, Ekouevi DK, Inwoley A, Chaix ML, Burgard M, Bequet L, Viho I, Leroy V, Simon F, Dabis F, Rouzioux C. Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol. 2004;42(9):4147–4153. doi: 10.1128/JCM.42.9.4147-4153.2004. - DOI - PMC - PubMed
Pre-publication history
-
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/14/461/prepub
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
